stockportfolio.pro
Stocks / URGN vs VIR
URGN vs VIR
UroGen Pharma Ltd. and Vir Biotechnology, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| UroGen Pharma Ltd. (URGN) | Vir Biotechnology, Inc. (VIR) | |
|---|---|---|
| Market cap | $1.4B | $1.4B |
| Revenue (latest FY) | $109.79M | $68.56M |
| Net income (latest FY) | $-153.49M | $-437.99M |
| Revenue growth (5y CAGR) | 56.2% | -2.1% |
| Net margin | -139.8% | -638.9% |
| Return on equity | 145.5% | -57.2% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 2 |
| Positive free cash flow | No | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open URGN — free Open VIR — freeFrequently asked questions
Which is bigger, URGN or VIR?
Vir Biotechnology, Inc. is larger by market capitalization — $1.4B versus $1.4B.
Which grows faster, URGN or VIR?
Over the last five fiscal years, UroGen Pharma Ltd. grew revenue faster — 56.2%/yr versus -2.1%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.